Business Standard

Market resilience in a pill: Pharma's formula for Q3 earnings upgrades

Rx for returns: Pharma firms' dominance in market recovery prescription

Indian market, markets
Premium

Photo: Bloomberg

Sundar Sethuraman

Listen to This Article

Pharmaceutical firms dominate the list of National Stock Exchange Nifty companies with the highest earnings upgrades after the announcement of the 2023–24 (FY24) October–December quarter (third quarter, or Q3) earnings.

On the other hand, information technology (IT), fast-moving consumer goods, and banking stocks dominate the list of downgrades.

The 2024–25 (FY25) earnings estimates for Cipla, Dr Reddy’s Laboratories, and Sun Pharmaceutical Industries have been upgraded by 8.2 per cent, 4.6 per cent, and 3.7 per cent, respectively.

HCLTech is an outlier in the IT pack with a 3.8 per cent earnings growth.

LTIMindtree, ITC, Hindustan Unilever, Axis Bank, and IndusInd Bank have seen their

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in